Managers

May IPO profiles: Biotech companies lead the way

Social Capital claims its CaaS initiative has exceeded expectations

Decibel Therapeutics rakes in $55 mln Series C

Boston-based Decibel Therapeutics, a developer of treatments for hearing loss and hearing-related disorders, has raised $55 million in Series C financing. The investors included Third Rock Ventures, GV, SR One, Regeneron Pharmaceuticals, Foresite Capital, Bessemer Venture Partners, Schroder Adveq, S-Cubed and Longevity.

Stealth BioTherpeutics racks up $100 mln

Newton, Massachusetts-based Stealth BioTherapeutics, a biopharmaceutical company, has secured $100 million in funding via two convertible notes. Nan Fung Technology's Pivotal Beta led the round with participation from other investors that included Atlantis Investment Management, BVCF Management, CMBC Capital Holdings, Kingdon Capital, Ocean Equity Partners, Sagamore Investments and Morningside Venture.

MetaProp wraps up second venture fund at $40 mln

MetaProp has closed its second venture fund at $40 million. MetaProp Ventures II will invest between $150,000 and $2 million in up to 40 new PropTech software, internet of things hardware and tech-enabled services startups. The fund's limited partners include RXR, PGIM Real Estate, Cushman & Wakefield, CBRE, JLL Spark and Altus Group.

Act One Ventures targets $30 mln for sophomore fund

Act One Ventures is seeking to raise $30 million for its second fund, according to an SEC filing. The Los Angeles-based venture firm invests in "business software at the seed stage, and in commercially viable scientific research ready to transition out of the lab."

Children's behavioral health company Mightier attracts $2.4 mln

Mightier, a children's behavioral health company that was founded out of Boston Children's Hospital, has has raised $2.4 million in seed funding. Slow Ventures led the round with participation from other investors that included Bolt, Founder Collective and Project 11.

Alpha Biopharma picks up Series A funding

Alpha Biopharma Inc, a biopharmaceutical company for the Chinese and global markets, has closed $37 million in its $65 million Series A funding round. Qiming Venture Partners led the round with participation from other investors that included TF Fund and the LYZZ Healthcare Venture Fund. In conjunction with the funding, Dr. William Hu, managing partner of Qiming Venture Partners, will join Alpha Biopharma's board of directors.

Social Capital reins in ambitious growth-stage investment plans

Impact America Fund to raise $50 mln venture-capital fund

Impact America Fund has set out to raise a $50 million venture-capital fund, according to a filing with the SEC.